These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26988986)

  • 1. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
    Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
    Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
    Passero FC; Ravi D; McDonald JT; Beheshti A; David KA; Evens AM
    Br J Haematol; 2020 Jan; 188(2):295-308. PubMed ID: 31452195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixazomib Induces Apoptosis and Suppresses Proliferation in Esophageal Squamous Cell Carcinoma through Activation of the c-Myc/NOXA Pathway.
    Wang T; Zhang P; Chen L; Qi H; Chen H; Zhu Y; Zhang L; Zhong M; Shi X; Li Q
    J Pharmacol Exp Ther; 2022 Jan; 380(1):15-25. PubMed ID: 34740946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
    Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
    Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
    Engür S; Dikmen M
    Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
    Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
    Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
    Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
    Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
    PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy for EBV-Associated B-cell Neoplasms.
    Ganguly S; Kuravi S; Alleboina S; Mudduluru G; Jensen RA; McGuirk JP; Balusu R
    Mol Cancer Res; 2019 Apr; 17(4):839-844. PubMed ID: 30487243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
    Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
    Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
    Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
    Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
    Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
    Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
    Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
    Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
    Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
    Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
    Ouyang Q; Chen G; Zhou J; Li L; Dong Z; Yang R; Xu L; Cui H; Xu M; Yi L
    Neuro Oncol; 2016 Feb; 18(2):216-26. PubMed ID: 26180082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.